What question did this study set out to answer?

To investigate the phenotypic trajectories and persistence of infused CAR+ and non-engineered CAR− T cells and evaluate their relationship to patient immune recovery.

November 27, 2023Nature CommunicationsOpen Access

CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies

View Full Paper

Ask AI

Bookmark

Authors

RLRaymond H. Y. LouieHong Kong University of Science and Technology CCCurtis CaiKarolinska Institutet JSJerome SamirThe University of Sydney

Discussion

Member takes

Implication

Clinical trial reveals parallel differentiation of CAR+ and CAR− T cells into NK-like subsets in B cell malignancies, indicating non-CAR signals track immune recovery.

Key Points

To investigate the phenotypic trajectories and persistence of infused CAR+ and non-engineered CAR− T cells and evaluate their relationship to patient immune recovery.
Conducted single-cell multi-omics analysis of CAR+ and CAR− T cells pre- and 1-month post-infusion from patients receiving donor-derived 4-1BB CD19 CAR T cells in the CARTELL trial (ACTRN12617001579381).
Validated findings using longitudinal mass cytometry in an independent cohort of 31 patients with large B cell lymphoma treated with CD19 CAR T cell therapy.
Observed that CAR+ and CAR− T cells share post-infusion differentiation trajectories, undergoing clonal expansion into natural killer (NK)-like subsets across heterogeneous phenotypes.
Identified that the presence of NK-like subsets in both CAR+ and CAR− T-cell populations correlates with clinical outcomes at 6 months post-infusion.

Cite This Study

Louie et al. (2023) studied this question.

synapsesocial.com/papers/6a7628c0be276543018c5bce https://doi.org/10.1038/s41467-023-43656-7

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial reveals parallel differentiation of CAR+ and CAR− T cells into NK-like subsets in B cell malignancies, indicating non-CAR signals track immune recovery.

CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies

Discussion

Member takes

Implication

Key Points

Cite This Study

CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider